Loading...
The remarkable success of antiretroviral therapy (ART) has greatly improved outcomes for people living with HIV. Among the many consequences is that a growing number of persons will require ART for decades, which will sharpen the focus on cost-conscious prescribing practices.
To compare the cost-effectiveness of five common ART regimens, investigators conducted a retrospective cohort study involving 491 patients starting initial treatment at an HIV clinic between 2007 and 2012. Patients received regimens containing tenofovir and emtricitabine plus one of the following five agents: efavirenz, rilpivirine, raltegravir, ritonavir-boosted atazanavir, or ritonavir-boosted darunavir. Drug effectiveness was based on durability of treatment response…